Exhibit E


Find more with Guardant.
Guardant360 captures mutations as low as 0.001% MAF.[1]
The right test matters.
Mutations identified on Guardant360 below Tempus xF+'s limit of detection[†]:
36% of ESR1 mutations[‡]
19% of EGFR mutations[§]
See the comparison:
Can the liquid biopsy you use find these patients?
MAF: Mutant Allele Fraction.
[†]Based on publicly available information for SNV detection on tempus.com as of September 2024; 2024-02.
[‡]Comparison against over 400,000 patient samples tested with Guardant360 CDx or Guardant360 liquid biopsy. Includes mis-sense variants in codons 310-547.
[§]Comparison against over 400,000 patient samples tested with Guardant360 CDx or Guardant360 liquid biopsy. Includes L858R, T790M, S768I, L861Q, G719X, exon 19 deletion and exon 20 insertion.
Reference: 1. Guardant360 Specification Sheet. 2024.
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
© 2024 Guardant Health, Inc. All rights reserved. MKT-000449 R1.
GUARDANT